HYDrochlorothiazidE compared to valsartan to treat arterial hypertension in patients with Hypertrophic obstructive CardioMyopathy – the multicenter, randomized, double-blind, controlled, crossover HYDE-HCM Trial

Condition studied

Hypertrophic cardiomyopathy

Investigational medicinal product(s)

Eligibility

Primary endpoint

Difference in absolute change of peak LVOT gradient at rest from before to after the treatment period between the two interventions

Endpoint detail

Difference of absolute changes between the two intervention groups of Peak LVOT gradient after Valsalva-Maneuver, Difference of absolute changes between the two intervention groups of left ventricular systolic pressure calculated from brachial blood pressure and LVOT gradient, Difference of absolute changes between the two intervention groups of Kansas City Cardiomyopathy Questionnaire (KCCQ-23 Score), Difference of absolute changes between the two intervention groups of EQ5D5L score, Difference of absolute changes between the two intervention groups of NT-proBNP, Difference of absolute changes between the two intervention groups of High-sensitive Troponin T/I, Difference of absolute changes between the two intervention groups of Interleukin-6, Difference of absolute changes between the two intervention groups of pVO2 during CPET (CPET sub-study), Difference of absolute changes between the two intervention groups of mean systolic postprandial office blood pressure, Difference of absolute changes between the two intervention groups of mean diastolic postprandial office blood pressure, Number of serious adverse events (SAEs), Difference of absolute changes between the two intervention groups of NYHA class